A Prospective Randomised Trial of Nifedipine Versus Placebo in Preterm Labour

IFFATARA¹, HASHINABANU²

Abstract:
Objective: To evaluate nifedipine as a tocolytic agent and measure the side-effects

Methods: Prospective randomized study of 89 singleton pregnancies with preterm labour between 30-34 weeks of gestation. The capacity to delay delivery 48 h, 7 days, till 36 weeks were the outcome variable assessed.

Results: Nifedipine could successfully prolong delivery in about 82% of cases. There were fewer side-effects. Main side-effects were flushing and head-ache. Most of the patients complained of no side-effects.

Conclusion: Nifedipine is a well tolerated tocolytic drug with fewer side-effects.

Key word: Nifedipine, tocolysis, preterm labour

Introduction:
Preterm labour is defined as the presence of uterine contractions of sufficient frequency and intensity to effect progressive effacement and dilatation prior to term gestation. Preterm labour and preterm births occur in approximately 12% of all pregnancies and is the leading cause of neonatal death in the United States as well as in the developing countries¹. In addition, preterm birth accounts for 70% of neonatal morbidity, and mortality, and health care spent on the neonate².

Despite the current use of material, effort and money in perinatal medical technology neonatal mortality rates continue to remain high. Implementation of effective risk identification, strategies and programmes for the prevention of preterm labour may lead to successful reduction of perinatal morbidity and mortality associated with prematurity. This in turn requires both an improved understanding of the psychosocial risk factors, etiology, mechanisms of preterm labour, and programmes for accurate identification of pregnant women at risk of premature labour and delivery³.

Until an etiological treatment is found for preterm labour, treatment is based on preventing unwanted uterine contractions. Several therapeutic attempts have been made to inhibit uterine activity such as ethanol, prostaglandin synthetase inhibitors, magnesium sulphate, ritodrine and beta-sympathomimetics. The side effects as well as the limited success have stimulated the investigators to search for new drugs such as oxytocin antagonists, calcium channel openers and calcium channel blockers⁴.

Nifedipine, a calcium channel blocking agent inhibits smooth muscle contraction by impeding the flow of calcium across the muscle cell membrane.

The aim of the study was to evaluate the tocolytic efficacy of nifedipine in preventing preterm labour and to evaluate the side effects.

Material and Methods
The study was conducted in the Institute of Child & Mother Health Matuail Dhaka & a private hospital, between January 2005 till December 2008. Eighty nine patients presenting with preterm labour between 30-34 weeks with singleton pregnancy and intact membrane were included in the study. Preterm labour was diagnosed by minimum of four contractions in 30 min. and cervical dilatation less than 3 cm. The subjects who met the inclusion criteria were randomized to receive either oral nifedipine or placebo by lottery method. There were 45 patients in the nifedipine group and 44 in the placebo group. Written consent was obtained from them. Women were considered to enroll for the study if preterm labour occurred between 30 and 34 weeks of singleton pregnancy and intact membrane. Exclusion criteria

1. Associate Professor, Dhaka Medical College
2. Assistant professor, Institute of Child and Mother Health
were cervical dilatation more than 3 cm, evidence of maternal infection, vaginal bleeding, severe PE, fetal growth restriction and oligohydramnios. Evaluation for the presence of genital infection was done by WBC count and some selected clinical parameters like uterine tenderness, maternal temperature, and foul smelling vaginal discharge. High vaginal swab was sent for routine examination and culture. Blood pressure monitoring was done regularly.

Nifedipine tocolysis was started with a loading dose of 30 mg (20 mg oral and 10 mg sublingually) followed by 20 mg every 4-6 hourly depending on the uterine activity. If uterine contraction was not subsided within 12 hrs of starting the treatment the case was considered as treatment failure. Subsidence of contraction was defined by absence of subjective feelings of pain by the patient. To measure the efficacy of this drug to postpone delivery three indicators were used- delay of labour for 48 hrs, for 7 days, continuation of pregnancy till 36 weeks. Side effects like head-ache, dizziness, muscle cramps, nausea and low blood pressure were evaluated. The patients remained at bed rest for 72 hours. After tocolysis the patients were discharged from the hospital after seven days with advice to come for check-up every weekly.

Because the samples were not uniformly distributed, they were analyzed using non-parametric statistics Kreskas –Wallis U –tests. Significance was set at 0.05. Data were expressed as mean ± standard error of the mean (S.E.M). Effect of tool sets was calculated by chi-square test. Significance was set at 0.05.

Results

The characteristics of both groups are detailed in table 1. The groups were comparable in maternal age, parity, gestational age and Bishop scoring.

Thirty five women (77.8%) assigned to nifedipine had successful tocolysis (delay of delivery > 48 hrs). This group remained un-delivered till at the end of seven days. The end point of 36 weeks of pregnancy could be achieved by 2 patients (4.4%). Failure of tocolysis was diagnosed in 8 patients (17.8%). Among the placebo group tocolysis for more than 48 hours could be achieved by only 5 (11.4%). The rest of the patients (88.6%) delivered within 12 hours.

Maternal side- effects were less in the nifedipine group. Twenty patients (44.7%) had no side-effects. Eighteen patients (40%) complained of flushing and rest seven patients (15.6%) had head-ache and vertigo. The placebo group had no side-effects.

### Table-I

**Characteristics of the study population**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Nifedipine N=45</th>
<th>Placebo N=44</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Years)</td>
<td>21±2.0</td>
<td>22 ±1.5</td>
<td>NS</td>
</tr>
<tr>
<td>Primipara</td>
<td>17±2.0</td>
<td>15 ±2.0</td>
<td>NS</td>
</tr>
<tr>
<td>Prenatal visit</td>
<td>7.5±1.4</td>
<td>8.4±1.2</td>
<td>NS</td>
</tr>
<tr>
<td>H/O previous preterm labor</td>
<td>3</td>
<td>1</td>
<td>NS</td>
</tr>
<tr>
<td>Gestational age</td>
<td>32.5±0.5</td>
<td>32.6±1.5</td>
<td>NS</td>
</tr>
<tr>
<td>Bishop score at diagnosis</td>
<td>2.9±0.94</td>
<td>2.6±0.89</td>
<td>NS</td>
</tr>
</tbody>
</table>

### Table-II

**Prolongation of pregnancy (chi-square test)**

<table>
<thead>
<tr>
<th></th>
<th>Nifedipine N=45</th>
<th>Placebo N=44</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>&gt;48 hours - 7 days</td>
<td>35</td>
<td>77.8</td>
</tr>
<tr>
<td>Upto 36 weeks</td>
<td>02</td>
<td>4.4</td>
</tr>
<tr>
<td>Failure</td>
<td>08</td>
<td>17.8</td>
</tr>
</tbody>
</table>

X² = 44.8 which is more than the table value 3.84 so p value is, <.05
Discussion:
It is well documented that the efficacy of nifedipine in suppressing preterm labour appears to be as good as and possibly better than, ritrodine and terbutaline. It also appears equivalent in its ability to prolong pregnancy.5,6

One study has compared nifedipine with magnesium sulphate and ritrodine.5, 6 They found tocolytic activity more or less same but side-effects were more in the ritrodine group. Papatsoninis et al7 randomized 185 women in preterm labour between 20 and 33 weeks to receive either intravenous ritrodine or oral nifedipine. The authors defined preterm labour as either one contraction or more every ten minutes. The dosage regimen was 10 mg nifedipine every 15 minutes for the first hour until contraction stopped (to a maximum of 40 mg). Then a daily dose of slow release nifedipine 60-160 mg depending on the amount needed in the first hour. Significantly fewer number of women taking nifedipine delivered within 24 hours, within 48 hours and within 7 days in comparison to ritrodine. Twelve women discontinued ritrodine because of side-effects, compared with none taking nifedipine. Fetal outcome was similar, with no difference in Apgar scores or in arterial or venous pH measurement at birth. There were significantly fewer admissions to the neonatal intensive care unit in the nifedipine group.

Kupferminc8 undertook a randomized trial including 71 women to compare nifedipine and ritrodine, and showed a similar prolongation of pregnancy for 48 hours, 7 days and until 36 weeks. Nifedipine was administered in an initial dose of 30 mg followed by further 20 mg 90 minutes later if uterine contractions persisted. A maintenance dose of nifedipine was then given orally every 8 hours. Eleven women with twin pregnancies were included in this trial; of the six that received nifedipine three delivered after 36 weeks gestation, compared to three of the five women who received ritrodine. These results have shown comparable efficacy of nifedipine and ritrodine in suppressing preterm delivery.

Glock and Morales9 found nifedipine to be as effective as magnesium sulphate in delaying delivery for 48 hours, with success rate 92 % and 93 % respectively. McLaughin et al10 showed these two drugs had similar efficacy in prolonging pregnancy and preventing birth before 37 weeks of gestation.

A major advantage noted in these studies is the reduced amount of maternal side effects reported with the use of nifedipine than with ritrodine or terbutaline. A systematic review in the Cochrane Library,11 comparing nifedipine and the beta-sympathmimetic drugs showed that nifedipine reduces the number of deliveries of newborn infants weighing less than 2500gm, but the number of infants admitted to the neonatal intensive care unit was increased. There was no difference in the stillbirth or neonatal death rate.

The tocolytic efficacy of nifedipine in the present study is 82%, which is statistically significant and is comparable with ritrodine, terbutaline or magnesium sulphate as shown in other studies.7-9 Since some of the drugs like terbutaline are not available and facilities for ICU support are needed for terbutaline and ritrodine, so alternatively nifedipine can be recommended as a tocolytic agent as it has fewer side effects. The dosage used in the present study was similar to the dose used in Kupfermins et al.8 It was seen that successful tocolysis can be achieved with the given dosage.

The concern for side-effects is an important factor for the choice of some of the tocolytic drugs like beta-mimetic. The various side effects in ritrodine treated group were tremor, palpitation, and nervousness and less important headache and chest pain or dizziness.9 In the present study side effects of nifedipine were less frequent and severe flushes and headache being the most discomforting problem. Similar side effects for nifedipine were also reported by other authors.12 The present study provides data supporting nifedipine as a safe tocolytic agent, better tolerated and with less maternal side-effects. Though the series is small but still multicenter trial can be done for evaluating the tocolytic efficacy of nifedipine.

References:
4. MorrisonJJ, Ashford MLJ, Khan RN et al . The effects of potassium channel openers on isolated


